Therapy targeting KRAS G12V mutations in lung, colon, and pancreatic cancers
Official title: Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
Funded at Enfuego Therapeutics INC. · NIH-11135580 · Data updated 2026-11-12
Developing a precision RNA-based therapy that aims to shut off the KRAS G12V mutation in people whose tumors are driven by that change.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Enfuego Therapeutics INC. NIH-funded |
| Lab location | 1 site (Pittsboro, United States) |
| Project start | July 5, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $919,020 |
| NIH project number | 5R44CA284932-03 |
| Project ID | NIH-11135580 on NIH RePORTER |
Who could benefit from this research
✓Could help
People whose cancers test positive for the KRAS G12V mutation—common in some lung, colorectal, and pancreatic cancers—would be the ideal candidates for future trials.
✕Less likely to help
People without the KRAS G12V mutation or whose cancer relies on different genetic drivers would likely not benefit from this approach.
What this research studies
The team is creating an RNA interference drug designed to selectively silence the mutant KRAS G12V gene while sparing the normal KRAS needed by healthy cells. They are using chemical modifications and a ligand that helps deliver the RNA drug to tumor tissues. Work includes laboratory experiments and animal studies to measure how well the drug reaches tumors, knocks down the mutant RNA, and how safe it appears. If preclinical results are favorable, the program would move toward clinical testing in people with KRAS G12V tumors.
Why it matters
Potential benefit: If successful, this could offer a mutation-specific treatment that slows tumor growth with fewer effects on normal tissues.
How similar studies have gone: Drugmakers have had clinical success targeting KRAS G12C with small molecules, but targeting G12V is newer and RNAi approaches for this mutation are still largely experimental.
Where this research is happening
-
Enfuego Therapeutics INC.
Pittsboro, United States Active
Researchers
- Principal investigator: Stanland, Lyla — Enfuego Therapeutics INC.
- Study coordinator: Stanland, Lyla
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.